Small bowel transplantation in children: an immunohistochemical study of intestinal grafts

G Fromont1, N Cerf-Bensussan, N Patey

  • 1Service d'Anatomie et de Cytologie Pathologiques, Hôpital Necker-Enfants Malades, Paris, France.

Gut
|December 1, 1995
PubMed

Insights

Neonatal small bowel allografts show better tolerance in children with short bowel syndrome. Immunohistochemistry aids in monitoring transplants and reveals lower immunogenicity in neonatal grafts, predicting fewer rejection episodes.

Area of Science:

  • Transplantation immunology
  • Gastroenterology
  • Surgical pathology

Background:

  • Short bowel syndrome necessitates intestinal transplantation.
  • Graft rejection is a significant challenge in small bowel allografting.
  • Neonatal grafts may offer improved outcomes compared to adult or pediatric grafts.

Purpose of the Study:

  • To define immunohistochemical markers of rejection in intestinal allografts.
  • To compare the immunogenicity of neonatal versus older donor small bowel grafts.
  • To assess the utility of immunohistochemistry in predicting transplant rejection.

Main Methods:

  • Immunohistochemical analysis of 85 intestinal biopsy specimens from pediatric patients.
  • Evaluation of immune cell infiltrates (CD3+, CD8+, CD25+, CD68+) and adhesion molecules (MHC class II, E-selectin).
  • Comparison of neonatal grafts with grafts from pediatric and adult donors.

Main Results:

  • Acute rejection associated with CD3+, CD8+, CD25+ T cells, CD68+ macrophages, MHC class II on enterocytes, and E-selectin on endothelial cells.
  • Immunohistochemistry predicted rejection 48 hours prior via CD25+ T cells.
  • Neonatal grafts showed no significant difference in macrophages or selectin expression but lacked MHC class II on epithelium and had fewer intraepithelial lymphocytes.

Conclusions:

  • Immunohistochemistry is a valuable tool for monitoring intestinal transplant rejection.
  • Neonatal small bowel allografts exhibit reduced immunogenicity, potentially explaining their better clinical tolerance.
  • Lower expression of MHC class II on neonatal epithelium and fewer intraepithelial lymphocytes contribute to improved graft acceptance.

Related Concept Videos